Key Statistics for SLP
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (08/2014)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (USD)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SLP
- Net Income (M/USD)
Simulations Plus, Inc. develops drug discovery and development simulation software, which is licensed to and used in the conduct of drug research for pharmaceutical companies worldwide. The Company's other businesses are based on its proprietary software technologies and provide support for the emerging pharmaceutical enterprise.
More Company Profile & Key Executives for SLP
|Walter S Woltosz "Walt"Chairman/President/CEO||John R KneiselChief Financial Officer|
|Michael BolgerChief Scientist||John A DibellaVP:Marketing & Sales|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.